IRIS
DI GIACOMO, ANNA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.961
EU - Europa 6.803
AS - Asia 6.062
SA - Sud America 1.249
AF - Africa 328
OC - Oceania 15
Totale 23.418
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.757
SG - Singapore 2.301
RU - Federazione Russa 1.854
IT - Italia 1.483
CN - Cina 1.476
BR - Brasile 1.027
IE - Irlanda 980
VN - Vietnam 778
GB - Regno Unito 679
HK - Hong Kong 514
FR - Francia 421
DE - Germania 332
SE - Svezia 285
KR - Corea 243
ZA - Sudafrica 219
BD - Bangladesh 213
UA - Ucraina 186
FI - Finlandia 179
IN - India 155
NL - Olanda 118
ES - Italia 94
CA - Canada 85
AR - Argentina 84
MX - Messico 77
EC - Ecuador 46
AT - Austria 42
IQ - Iraq 42
PL - Polonia 39
JP - Giappone 36
KE - Kenya 35
ID - Indonesia 34
TR - Turchia 32
SA - Arabia Saudita 23
CO - Colombia 20
AZ - Azerbaigian 18
PK - Pakistan 18
CL - Cile 17
AE - Emirati Arabi Uniti 16
IR - Iran 16
PY - Paraguay 15
UZ - Uzbekistan 15
JO - Giordania 14
VE - Venezuela 14
AL - Albania 13
AU - Australia 13
MA - Marocco 13
MY - Malesia 13
BE - Belgio 12
NP - Nepal 12
PE - Perù 12
PH - Filippine 12
LT - Lituania 11
NG - Nigeria 11
DZ - Algeria 10
CH - Svizzera 9
EG - Egitto 9
KZ - Kazakistan 9
JM - Giamaica 8
KG - Kirghizistan 8
LB - Libano 8
TN - Tunisia 8
BG - Bulgaria 7
BH - Bahrain 7
BO - Bolivia 7
IL - Israele 7
OM - Oman 7
CR - Costa Rica 6
CZ - Repubblica Ceca 6
ET - Etiopia 6
NO - Norvegia 6
TH - Thailandia 6
UY - Uruguay 6
BY - Bielorussia 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
HN - Honduras 5
PT - Portogallo 5
SV - El Salvador 5
EE - Estonia 4
MD - Moldavia 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
AM - Armenia 3
AO - Angola 3
BA - Bosnia-Erzegovina 3
CI - Costa d'Avorio 3
GR - Grecia 3
HU - Ungheria 3
KH - Cambogia 3
LK - Sri Lanka 3
LV - Lettonia 3
RO - Romania 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
BN - Brunei Darussalam 2
CG - Congo 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
HR - Croazia 2
Totale 23.388
Salva come PNG Salva come JPEG
Città #
Dallas 1.536
Singapore 1.307
Dublin 975
Fairfield 817
Ashburn 656
Santa Clara 545
Moscow 519
San Jose 497
Hong Kong 492
Southend 453
Woodbridge 399
Hefei 380
Beijing 370
Seattle 349
Houston 320
Cambridge 299
Wilmington 293
Siena 268
Ho Chi Minh City 248
Seoul 232
Milan 220
Johannesburg 198
Lauterbourg 183
Princeton 170
The Dalles 163
Jacksonville 159
Los Angeles 158
Council Bluffs 152
New York 144
Hanoi 136
Ann Arbor 134
Florence 125
Chandler 117
Helsinki 113
Dong Ket 101
Rome 99
San Mateo 84
Shanghai 84
São Paulo 80
Amsterdam 67
Dearborn 66
Buffalo 59
Málaga 54
Bengaluru 51
Redondo Beach 51
Nuremberg 49
San Diego 47
Chicago 44
London 44
Lappeenranta 43
Munich 42
Frankfurt am Main 37
Orem 37
Rio de Janeiro 36
Brooklyn 34
Denver 33
Haiphong 31
Montreal 30
Stockholm 30
Tokyo 30
Warsaw 30
San Francisco 28
Guangzhou 27
Nanjing 27
Vienna 27
Chennai 26
Naples 25
Phoenix 25
Da Nang 24
Mexico City 23
Toronto 22
Belo Horizonte 21
Manchester 21
Portsmouth 21
Bologna 20
Guayaquil 20
Atlanta 19
Boardman 17
Borgo San Lorenzo 17
Cascina 17
Düsseldorf 17
Fremont 17
Perugia 17
Poplar 17
Baku 16
Modena 16
Columbus 15
Ninh Bình 15
Palermo 15
Tianjin 15
Turku 15
Bari 14
Brasília 14
Curitiba 14
Empoli 14
Sesto Fiorentino 14
Barnet 13
Boston 13
Dhaka 13
Hangzhou 13
Totale 15.244
Salva come PNG Salva come JPEG
Nome #
Neurological adverse events of ICI therapy: A ten-year comprehensive management from a multidisciplinary team 500
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 346
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 329
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 318
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 261
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 261
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 249
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 248
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 244
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 240
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches 224
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 224
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 222
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 222
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 222
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. 218
Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/ mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study 218
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 212
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 209
Back to simplicity: A four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients 209
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 208
Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 204
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 203
The italian experience on the feasibility and safety of ipilmumab therapy in pretracted metastatic melanoma patients 198
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 197
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 194
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 193
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 190
Biomolecular Predictors of Recurrence Patterns and Survival in IDH-Wild-Type Glioblastoma: A Retrospective Analysis of Patients Treated with Radiotherapy and Temozolomide 188
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients 188
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 187
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 185
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID 184
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 184
A novel microRNA signature for the detection of melanoma by liquid biopsy 183
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial 181
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 178
Immunotherapy targeting immune check-point(s) in brain metastases 175
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 174
Perspectives on the role of “-Omics” in predicting response to immunotherapy 172
A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial 171
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 170
Predictors of responses to immune checkpoint blockade in advanced melanoma 170
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab 169
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 168
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications 163
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 162
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 162
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab 162
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 160
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study. 160
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients 158
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 156
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? 154
Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? 154
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 153
Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop” 150
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria 150
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond 149
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: A case report 149
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells 148
Challenges in lung cancer therapy during the COVID-19 pandemic 148
Correction to: Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery (Journal of Neuro-Oncology, (2024), 10.1007/s11060-024-04818-9) 145
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications 144
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile 142
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis 142
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 140
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma 139
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) 139
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients 139
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 139
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma 137
Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial 136
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial 135
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial 135
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study 134
Ipilmumab in pretreated metastatic uveal melanoma patiens; safety and clinical efficacy 133
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients 133
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial 132
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial 132
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238 131
Can epigenetics have a clinical impact in the treatment of melanoma? 130
Epigenetics meets immune checkpoints 130
Long-term follow-up of a papillary tumor of the pineal region: addendum to a case report 130
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma 130
Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial 130
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study 130
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy 129
Nivolumab plus ipilimumab in melanoma brain metastases 129
The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients 127
Mutational concordance between primary and metastatic melanoma: A next-generation sequencing approach 126
Effects of molecular heterogeneity on survival of patients with BRAFV600-mutated melanoma treated with vemurafenib with or without cobimetinib in the coBRIM study 125
Dietary compounds and cutaneous malignant melanoma: Recent advances from a biological perspective 123
From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma 123
Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery 122
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma 122
Adjuvant nivolumab for stage III/IV melanoma: Evaluation of safety outcomes and association with recurrence-free survival 122
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 120
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study 120
Serum lactate dehydrogenase as a prognostic marker for treatment response in IDH wild-type glioblastoma patients undergoing stupp protocol 120
Totale 17.423
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.621
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.621
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021219 0 0 0 0 0 0 0 0 0 0 0 219
2021/2022989 43 87 91 20 18 65 34 42 74 137 123 255
2022/20231.326 106 86 212 113 58 235 42 67 92 56 219 40
2023/20241.661 63 62 152 61 49 393 551 62 44 24 38 162
2024/20254.287 121 148 319 234 459 278 139 175 479 323 455 1.157
2025/202611.472 790 1.430 1.420 1.350 2.273 396 1.221 468 399 732 622 371
Totale 24.047